anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: This paper aims to instigate discussion and publication of methodologies applied to enhance quality management through comprehensive scientific reports. It provides a detailed description of the design, implementation, and results of the quality control program employed in the SMESH study.
METHODS: Cross-sectional, multicenter, national study designed to assess the prevalence of human papillomavirus in sex workers and in men who have sex with men (MSM). Respondent-driven sampling recruitment was used. An online system was developed for the study and checkpoints were defined for data entry. The system checked the quality of biological samples and performed a retest with part of the sample.
RESULTS: A total of 1.598 participants (442 sex workers and 1.156 MSM) were included. Fifty-four health professionals were trained for face-to-face data collection. The retest showed Kappa values ranging between 0.3030 and 0.7663.
CONCLUSION: The retest data were mostly classified as indicating a strong association. The data generated by the checkpoints showed the successful implementation of the quality control program.
The invention discloses a traditional Chinese medicine for treating aconuresis. The medicine is characterized in that the medicine is prepared by the pharmaceutical raw materials with the following mixing ratio by weight: 30 parts of prepared rehmannia root, 15 parts of multiflower knotweed vine, 10 parts of cherokee rose, 10 parts of red raspberry, 15 parts of gordon euryale, 10 parts of lotuses stamen, and 15 parts of ecipta albas. Pure Chinese medicinal materials are selected in the invention and all components meet the relevant drug regulations; the medicine adopts the comprehensive functions of the Chinese medicinal herbs, so the medicine can cure the aconuresis; furthermore, the medicine has no chemical sweetness agent, no toxicity and no harm to human body. The medicine of the invention has a bit sweet but no bitterness and is convenient for taking. According to years of clinic observation of the patient cases, a treatment course lasts for six days, the medicine is taken twice per day, with 50ml each time and has cured over 3000 patients completely and the total efficiency is 99 percent. The medicine of the invention can be widely applied in the clinic treatment of aconuresis.
The COVID-19 open trial phase arm did not include randomization or control arm. All participants received the EMPOWER intervention. Assessments will occur pre-intervention, immediately post-intervention, and then 1-month and 3-months from post-intervention assessment.
PURPOSE:To improve the aging stability of a vitamin K injection useful for the remedy of hypo-prothrombinemia caused by biliary atresia and bilifaction insufficiency, by adding the propylene glycol ester of a specific fatty acid. CONSTITUTION:An extremely stable vitamin K injection containing the compound of formula [R is CH3(CH2)n; n is integer of 14-16]. The injection can be prepared as follows. 10pts.wt. of vitamin K (e.g. vitamin K1, vitamin K2, etc.) and 5pts.wt. of the compound of formula are mixed with a proper amount of a nonionic surface active agent such as sorbitan fatty acid ester, etc., and the mixture is molten under heating and agitation. About 500pts.vol. of hot distilled water is added to the molten mixture to obtain a homogeneous solution, which is added with 40-60pts.wt. of glucose and a proper amount of distilled water to obtain 1,000pts.vol. of the solution. The solution is treated by the conventional procedures for the preparation of injection. There is absolutely no clouding or precipitation of microscopic crystals with time.
PURPOSE: To assess factors that impact the risk of relapse in patients with noninfectious uveitis (NIU) who undergo adalimumab tapering after achieving remission.
DESIGN: Retrospective study.
METHODS: In this multicenter study, patients with NIU were treated with adalimumab and subsequently tapered. Patient demographics, type of NIU, onset and duration of disease, the period of inactivity before tapering adalimumab, and the tapering schedule were collected. The primary outcome measures were independent predictors of the rate of uveitis recurrence after adalimumab tapering.
RESULTS: Three hundred twenty-eight patients were included (54.6% female) with a mean age of 34.3 years. The mean time between disease onset and initiation of adalimumab therapy was 35.2 ± 70.1 weeks. Adalimumab tapering was commenced after a mean of 100.8 ± 69.7 weeks of inactivity. Recurrence was observed in 39.6% of patients at a mean of 44.7 ± 61.7 weeks. Patients who experienced recurrence were significantly younger than those without recurrence (mean 29.4 years vs 37.5 years, P = .0005), and the rate of recurrence was significantly higher in younger subjects (hazard ratio [HR] = 0.88 per decade of increasing age, P = .01). The lowest rate of recurrence was among Asian subjects. A faster adalimumab taper was associated with an increased recurrence rate (HR = 1.23 per unit increase in speed, P < .0005). Conversely, a more extended period of remission before tapering was associated with a lower rate of recurrence (HR = 0.97 per 10-weeks longer period of inactivity, P = .04).
CONCLUSIONS: When tapering adalimumab, factors that should be considered include patient age, race, and duration of disease remission on adalimumab. A slow tapering schedule is advisable.
Cardiovascular diseases are among the leading causes of death in industrialized countries. Medical therapy for these diseases has seen significant progress, much of which is based on agents interfering with the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, mineralocorticoid receptor antagonists, neprilysin inhibitors). However, these agents bear the side effect of reducing renal potassium (K+) excretion and may thus lead to elevation of blood K+ Levels (hyperkalemia). Hyperkalemia is a potentially life-threatening condition, which in its most severe forms requires immediate medical attention, since there is imminent danger of dangerous arrhythmias and sudden cardiac death. Therefore, hyperkalemia is a leading reason to withdraw potentially lifesaving therapy in a significant number of patients, which is considered to have a negative impact on patient outcomes. Recently, novel intestinal potassium binders have been shown to be efficient in reducing incidence and severity of hyperkalemia These compounds have very recently been shown to allow extending the benefits of antihypertensive therapy with spironolactone to patients with chronic kidney disease with refractory hypertension . Yet due to preanalytical problems as well as time and cost-restraints, out-patient monitoring of serum or plasma potassium levels has proven problematic.

The plasma potassium level and kinetics at two timepoints before and after a hemodialysis session as determined by either standard of care (i.e. ion selective electrode) will be compared to the potassium level measured in (i) saliva (salivary potassium \[K+Sa\]) or (ii) determined based on electrocardiogram (K+ECG). Patients suffering from end-stage renal disease undergoing hemodialysis (HD) frequently present with severe hyperkalemia prior to a HD session. During HD treatment, K+ levels undergo unphysiologically rapid changes due to K+ removal via HD as well as due to changes in acid-base status. Thus, HD patients represent a unique population in whom significant K+ derangements and rapid K+ Level changes predictably occur and where these phenomena can be investigated in a safe environment.
Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
FIELD: medicine, molecular biology. SUBSTANCE: invention relates to virus- -mediated transfer of DNA and method of the enhanced effectiveness of transduction of hemopoietic and other cells induced by retrovirus. Method involves infection of cells in the presence of fibronectin or its fragments. Fibronectin and its fragments enhance retrovirus-mediated transfer of genes in cells, in part, in hemopoietic cells including committed cell- -precursors and primary hemopoietic stem cells significantly. Invention relates to also the improved methods of somatic genetic therapy based on enhanced transfer of genes, hemopoietic cells population and novel constructions designated for enhancement of retrovirus-mediated transfer of DNA in cells and their use. Invention provides development of effective transfer of genetic material in mammalian cells without dangerous results and limitations. EFFECT: improved method of DNA transfer. 88 cl, 11 dwg, 4 tbl, 11 ex
Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
FIELD: molecular biology, medicine, immunology. SUBSTANCE: invention relates to preparing monoclonal antibodies showing immunostimulating effect. Hybridoma CNCM 1-1397 is prepared by immunization of mice with membrane preparation of Daudi cells followed by isolation of splenocytes and their fusion with myeloma cells. Hybridoma produces monoclonal antibodies showing immunostimulating effect and able to bind CD3 cells. Invention ensures to develop antitumor preparation that can be used for treatment and prophylaxis of cancer. EFFECT: valuable antitumor properties. 4 cl, 12 dwg, 12 tbl, 8 ex
The present invention relates to an external and enepidermic material. A paste is prepared from polyvinyl butyral, glycerol, alcohol, etc., and different medicines are added into the paste body to obtain products with different efficiency. The present invention is characterized in that after the present invention is applied on skin or a wound, a layer of air permeable waterproof film which closely clings to the skin is formed to block dust and bacteria outside and provide medicines inside, and thus, the skin does not need binding by gauze and rubberized fabric. The present invention is used for treating scratches, skin pains, muscular pains, nerve pains and other diseases, and overcomes the disadvantage that enepidermic medicines are easy to rub off. When applied to a suture part, the present invention can prevent infection and bring convenience for observation without having skin allergy. When not used, the present invention can be torn down in sheet shapes. The present invention has the advantages of easy production and low cost.
PROBLEM TO BE SOLVED: To obtain the subject composition harmless to human body and having triglyceride lowering action by including a curcumin as an active ingredient. SOLUTION: This composition is obtained by including one or more selected from a curcumin [e.g. 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione] and its derivative  e.g. demethoxycurcumin [4-hydroxy-cinnamoyl-(4-hydroxy-3- methoxy-cinnamoyl)methane]} as an active ingredient. The composition, when to be used as a pharmaceutical, can be administered by oral administration, intravenous injection, hypodermic injection or the like using a curcumin or its derivative, as necessary, combinedly with another lipid metabolism improving composition and the daily adult dose is preferably 1-30 mg/kg-body weight. The composition can be prepared as soft capsules, tablets, granuled or the like.
We will follow a prospective cohort of 558 patients, undergoing any elective surgery at Stanford Hospital. Subjects will undergo baseline and longitudinal testing via a (including NIH Patient-Reported Outcomes Measurement Information System- PROMIS measures of emotional distress). After surgery, participants will report weekly changes in opioid use, pain, and adverse events; and monthly changes in opioid misuse for 1 year.
The instant disclosure relates generally to oral inoculation and specifically to methods to prepare nasopharyngeal and oral material for oral inoculation of COVID-19. Severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) viral particles are collected from at least one of a nasopharyngeal specimen and an oral specimen each derived from a patient infected with SARS-CoV-2 or a SARS-CoV-2 variant. Mammalian cells (e.g., Vero-E6 and/or Vero-CCL81 cells) are infected with the SARS-CoV-2 viral particles to produce infected mammalian cells. The infected mammalian cells are cultured to produce a mammalian cell culture. SARS-CoV-2 viral particles are collected from the mammalian cell culture to produce isolated viral particles. The isolated viral particles are frozen to produce a frozen isolate. The frozen isolate is partitioned into a plurality of tablets each having a therapeutically effective amount of the SARS-CoV-2 viral particles. An enteric coating is applied to each tablet.
Dual Blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on benazepril hydrochloride and other agents that affect the RAS.

Do not coadminister aliskiren with benazepril hydrochloride in patients with diabetes. Avoid use of aliskiren with benazepril hydrochloride in patients with renal impairment (GFR < 60 ml/min).
The Teleprehabilitaiton intervention (also known as Surgery School) is a one-off group based education session delivered online. Video presentations of 8-10 key prehabilitation education areas will be facilitated by a live clinician facilitator who will introduce the educational content and answer any questions. All standardised video presentations during the session will be made available to participants through an online password-protected video repository hosted on a video platform after the session and will be available until their surgery.
A recombinant newcastle disease virus is provided to show similar antigenicity to a highly newcastle virus epidemic in Korean and Asian region and similar or significantly low pathogenicity compared with currently used vaccine strains, thereby being used as an in vivo vaccine and being usefully used for preparing an inactivated vaccine, a live vaccine and an in ovo vaccine. A recombinant newcastle disease virus strain comprises: an NP, P, M and L protein coding sequences of a weakly pathogenic newcastle disease virus having an amino acid sequence which is an amino acid sequence from 113th to 116th of an F protein and represented by the formula(2) of 113-X5X6X7X8-118; and an F and HN protein coding sequences of a highly pathogenic newcastle virus having an amino acid sequence which is an amino acid sequence from 113th to 116th of an F-protein and represented by the formula(1) of 113-X1X2X3X4-118, wherein a coding codon of the 115th amino acid of the F protein of the highly pathogenic newcastle virus is substituted by at least one selected from the group consisting of an alanine coding codon consisting of protein coding sequence GCA, GCC, GCG and GCU, an aspartic acid coding codon consisting of GAC and GAU, a phenyl alanine coding codon consisting of UUC and UUU, an isoleucine coding codon consisting of AUC and AUU, a leucine coding codon consisting of UUA and UUG, a serine coding codon consisting of UCA, UCC, UCG and UCU, a threonine coding codon consisting of ACC and ACU, a valine coding codon consisting of GUA, GUC, GUG and GUU, and a tyrosine coding codon consisting of UAC and UAU. In the formulae, each X1, X3 and X4 is independently arginine(R) or lysine(K); X2 is alanine, isoleucine, leucine, methionine, phenyl alanine, prolline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, threonine, tyrosine, aspartic acid, glutamic acid, arginine, histidine or lysine; each X5, X6 and X7 is independently alanine, isoleucine, leucine, methionine, phenyl alanine, prolline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, threonine, tyrosine, aspartic acid, glutamic acid, arginine, histidine or lysine, provided that in case of X5 and X7 being arginine or lysine are excepted; and X8 is arginine or lysine. The strain is deposited as a deposition no. KCTC 10984BP. A newcastle disease vaccine comprises the recombinant newcastle disease virus strain.
PURPOSE: To obtain a new flavonoid glycoside useful as an ingredient of a therapeutic agent for osteoporosis and an edible composition. CONSTITUTION: A compound of the formula (R1 and R2 are each H, OH or OCH3 ; R3 is H, COCH3 , COCH2 COOH or COCH2 CH2 COOH), e.g. 6''-O- succinylisoflavone. The flavonoid glycoside of the formula is contained in a plant of the family Leguminosae and its fermented material and obtained by extracting raw material soybeans or fermented soybeans fermented with Bacillus natto with an alcohol and purifying the resultant extract by a column chromatography. The flavonoid glycoside is orally administered to suppress the reduction in bone mass and prevent and treat osteoporosis. The glycoside has slight side effects and can safely by ingested as a food for a long period.
PROBLEM TO BE SOLVED: To obtain a dinoreburunamenine derivative-containing capsule. SOLUTION: This pharmaceutical composition consists of a capsule casing and a capsule-filling mixture. The capsule casing is composed of gelatin and optionally a plasticizer and other additives (e.g. a coloring agent and a sugar). The capsule-filling mixture contains 1-20 wt.% of a compound of the formula (R1 to R3 are each H, a halogen, a 1-5C alkyl or alkoxy, hydroxyl, trifluoromethyl, nitro, amino, etc.), or its salt, and a mineral oil, and it is a suspension or liquid-type mixture. The mixture is filled in the casing to prepare a soft capsule. A daily dose is 0.1-200 mg in oral administration, and a capsule contains, e.g. 0.5-50 mg of an active component.
Weight loss is a common factor reported in lowlanders traveling to high altitudes. Although the exact cause is unknown, studies have shown that weight loss at high altitude is associated with the amount of time and severity of the altitude exposure. Upon arrival to high altitude (≥ 5000 feet), numerous physiological adaptations occur that may promote weight loss, such as increased energy expenditure and reduced appetite. The breadth of current altitude research is limited by the logistical and monetary constraints of traveling to remote locations or access to an altitude chamber. A more logistically feasible alternative is the simulation of low oxygen conditions at sea level, using a commercially available tent and generator system to reduce ambient oxygen concentrations. The current research study will evaluate changes in resting metabolic rate, appetite, and heart rate variability following overnight exposure (8 h/night) to normobaric hypoxia (NH) or normobaric normoxic (NN). In randomized order, participants will sleep one night in NH conditions (\~15% oxygen; achieved with nitrogen dilution, equivalent to \~8500 feet elevation) and another night in NN (control) conditions (\~20% oxygen; achieved with nitrogen dilution, equivalent to \~1000 feet elevation). In the morning, following NH or NN exposure, resting metabolic rate will be measured using indirect calorimetry, appetite using an ad libitum buffet meal protocol, and heart rate variability by electrocardiogram. It is hypothesized that exposure to overnight NH will result in increased resting metabolic rate, decreased appetite, and decreased heart rate variability.
The invention relates to a pH sensitive nanoparticles prodrug with capacity of co-delivering multiple drugs, a preparation method and an application thereof. According to the invention, an external layer is polyethylene glycol possessing highly biological compatibility, a core is hydrophilic terminal bond and an antitumor drug doxorubicin (DOX), and the other hydrophobic antitumor drug curcumin (Cur) is coated through a hydrophobic effect. A structure is PEG-DOX-W-NPs. Under pH response condition, the nanoparticles prodrug can simultaneously release multiple antitumor drugs through disintegration for performing combination therapy effect. The provided pH sensitive nanoparticles prodrug has the advantages of good biology compatibility and long internal effect time. The preparation method has the advantages of simple process, good stability, and convenient operation and popularization.
Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent. The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein. In a preferred embodiment, a bioactive molecule having a short elimination half-time is incorporated as or into an active domain of the hybrid molecules of the invention, and the binding affinity of the peptide ligand domain prolongs the elimination half-time of the hybrid as compared to that of the bioactive molecule. Phage ELISA co 0.25I5 (M _-yo 1 ar-56S9 95 *Yol 92-570 -G-250 01Yo317-569 - . 98 Y0317-570 140 0.05 , .1 -010 9 10-7 10"6 icy 5 j(4D5 IgG]
The present invention describes a principle and a method suitable for developing, testing, preparing and using various amphipathy complexes, if necessary, modified macromolecules (such as polypeptides, proteins, etc.) or other chain molecules (such as suitable partial hydrophobic polynucleotide or polysaccharide) and an aggregate. The aggregate comprises the mixture of polarity and/or charged amphipathy substances and forms an extension surface capable of being freely suspended or supported. The method can be used for optimizing the aggregate. After the aggregate is associated with chain molecules having certain activity or useful functions, the aggregate is suitable to be used in vitro or in vivo in the fields, such as drug release, diagnosis or biologic/ catalysis. As the concrete embodiment, the present invention describes a small-bubble small-drop mixture comprising fat substances, such as loaded (associated) insulin, interferon, interleukin, nerve growth factors, calcitonin, immunoglobulin, etc.